Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience

Figure 1 Consort flow diagram showing inclusion and exclusion of patients in study population. Human epidermal growth factor receptor 2 positive (HER2+) invasive lobular carcinomas was defined as an immunohistochemistry score of 3+ or an immunohistochemistry score of 2+ with a HER2 to chromosome 17 ratio ≥ 2.0 for samples after 1 January 2014 and HER2 to chromosome 17 ratio ≥ 2.2 for samples before 1 January 2014 on fluorescence in situ hybridization testing[4]. ILC: Invasive lobular carcinomas; HER2: Human epidermal growth factor receptor 2; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization; HER2+: Human epidermal growth factor receptor 2 positive; HER2-: Human epidermal growth factor receptor 2 negative.